According to the Legislative Budget Board (LBB), HB 3554 is not expected to have a significant fiscal impact on the state. The Department of State Health Services (DSHS), which is tasked with providing administrative support to the newly created Texas Rare Disease Advisory Council, anticipates the need for one additional full-time equivalent (FTE) staff position to support the council’s operations. However, DSHS indicates that the associated costs can be absorbed within its current budget and resources, meaning no new appropriations or funding increases are necessary at this time.

The bill does not authorize any new spending, regulatory enforcement, or grantmaking authority. Instead, it establishes a volunteer advisory body that functions in a consultative role. Therefore, the fiscal footprint is limited to administrative support such as coordinating meetings, managing council communications, publishing reports, and handling logistics. Because this is not expected to require significant new infrastructure or staffing beyond the one support role, the overall cost to the state remains minimal.

There are no anticipated fiscal implications for local governments. The bill imposes no mandates on local jurisdictions, nor does it require any new local spending or participation in council operations. As such, HB 3554 is expected to have a negligible fiscal impact at both the state and local levels.

HB 3554 seeks to establish the Texas Rare Disease Advisory Council to advise state leaders on policies and strategies for improving outcomes for patients with rare diseases. While the intent is admirable and the need for improved understanding of rare disease issues is real, the bill nonetheless represents an incremental expansion of government, however modest, that gives rise to valid concerns for limited-government conservatives.

Although the bill creates no new regulatory authority and carries no significant fiscal impact, it nonetheless establishes a new state advisory body with formalized appointments, administrative support, and annual reporting obligations. This constitutes the creation of a new function of state government that could, over time, grow in scope, cost, or influence. Even advisory-only bodies require support infrastructure, invite mission creep, and often serve as precursors to future spending or programmatic proposals.

Moreover, the issues the council aims to address, diagnostic delays, research coordination, and treatment access, are challenges that could be better tackled through private sector innovation, nonprofit collaboration, and existing academic or medical partnerships without further embedding the state in health care matters. From a strict constitutionalist or fiscal conservative perspective, these well-meaning efforts are best left outside the purview of state government.

While the cause is noble and the bill is carefully crafted, Texas Policy Research recommends that lawmakers vote NO on HB 3554 as one guided by principle, not emotion.

• Individual Liberty: The bill empowers rare disease patients and their advocates by giving them formal representation in policy discussions. It enhances their visibility and input into state health strategies, which could lead to better access to treatments and support services. From this angle, it expands individuals’ ability to be heard in the public process. For liberty-minded individuals, any increase in state involvement in health-related policy, even advisory, may be seen as the first step toward broader state influence over personal medical decisions. Even absence of mandates, increased state coordination in rare disease matters could evolve into future policies that affect individual choice.
• Personal Responsibility: The bill neither impedes nor encourages personal responsibility directly. It does not create entitlements or dependency, but neither does it actively promote individual initiative. Instead, it creates a forum for stakeholders to advise government leaders, which has minimal bearing on personal accountability.
• Free Enterprise: The bill includes representatives from the biotechnology and insurance industries, suggesting a commitment to market-based solutions. The advisory role could lead to reduced barriers for innovation in rare disease treatments or highlight issues with insurance coverage that inhibit market access. Even without regulatory power, government-sanctioned advisory councils sometimes serve as precursors to future regulations or subsidies. Businesses may fear that today’s discussion becomes tomorrow’s red tape.
• Private Property Rights: The bill does not directly impact land use, ownership rights, or eminent domain. However, by avoiding mandates or enforcement authority, it maintains respect for private enterprise and personal health autonomy, an indirect support of property rights in the broader sense of self-ownership.
• Limited Government: This is where the bill most clearly conflicts with liberty principles. The bill creates a new state-level council, requires DSHS administrative support, and mandates annual reporting. Though these duties are limited and relatively low-cost, the structure represents a net expansion of state government. For constitutional conservatives, even advisory-only expansions, especially in health care policy, challenge the principle that government should only perform core, essential functions expressly authorized by the people.